The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease

Colomba Falcone; Diego Geroldi; Maria P. Buzzi; Enzo Emanuele; Yusuf Yilmaz; Jacopo M. Fontana; Luigi Vignali; Chiara Boiocchi; Ilaria Sbarsi; Mariaclara Cuccia

doi:10.1016/j.arcmed.2007.11.003

The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease

Colomba Falcone, Diego Geroldi, Maria P. Buzzi, Enzo Emanuele, Yusuf Yilmaz, Jacopo M. Fontana, Luigi Vignali, Chiara Boiocchi, Ilaria Sbarsi, Mariaclara Cuccia

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis. No data are currently available on the potential prognostic role of this polymorphism in patients with angiographically proven coronary artery disease (CAD). Hereto we sought to address this issue in a large consecutive cohort of patients undergoing coronary revascularization. Methods: A total of 643 CAD patients who underwent myocardial revascularization were followed for 4.2 years (interquartile range: 2.2-8.1 years). The rates of major cardiac adverse events (death, nonfatal myocardial infarction, and unstable angina) were compared according to the -374T/A RAGE polymorphism. Results: During a median follow-up period of 4.2 years, the study endpoint was reached by 126/643 patients (19.6%). We observed adverse cardiac events in 13.4% of patients with AA, 17.5% of those with AT, and 24.2% of those with TT genotype (p

Original language	English
Pages (from-to)	320-325
Number of pages	6
Journal	Archives of Medical Research
Volume	39
Issue number	3
DOIs	https://doi.org/10.1016/j.arcmed.2007.11.003
Publication status	Published - Apr 2008

Keywords

Genetics
Polymorphism
Prognosis
Receptor for advanced glycation end products

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/j.arcmed.2007.11.003

Cite this

The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease. / Falcone, Colomba; Geroldi, Diego; Buzzi, Maria P.; Emanuele, Enzo; Yilmaz, Yusuf; Fontana, Jacopo M.; Vignali, Luigi; Boiocchi, Chiara; Sbarsi, Ilaria; Cuccia, Mariaclara.

In: Archives of Medical Research, Vol. 39, No. 3, 04.2008, p. 320-325.

Research output: Contribution to journal › Article › peer-review

Falcone, Colomba ; Geroldi, Diego ; Buzzi, Maria P. ; Emanuele, Enzo ; Yilmaz, Yusuf ; Fontana, Jacopo M. ; Vignali, Luigi ; Boiocchi, Chiara ; Sbarsi, Ilaria ; Cuccia, Mariaclara. / The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease. In: Archives of Medical Research. 2008 ; Vol. 39, No. 3. pp. 320-325.

@article{33232a6581d54aa79c139fe12754435a,

title = "The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease",

abstract = "Background: The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis. No data are currently available on the potential prognostic role of this polymorphism in patients with angiographically proven coronary artery disease (CAD). Hereto we sought to address this issue in a large consecutive cohort of patients undergoing coronary revascularization. Methods: A total of 643 CAD patients who underwent myocardial revascularization were followed for 4.2 years (interquartile range: 2.2-8.1 years). The rates of major cardiac adverse events (death, nonfatal myocardial infarction, and unstable angina) were compared according to the -374T/A RAGE polymorphism. Results: During a median follow-up period of 4.2 years, the study endpoint was reached by 126/643 patients (19.6%). We observed adverse cardiac events in 13.4% of patients with AA, 17.5% of those with AT, and 24.2% of those with TT genotype (p ",

keywords = "Genetics, Polymorphism, Prognosis, Receptor for advanced glycation end products",

author = "Colomba Falcone and Diego Geroldi and Buzzi, {Maria P.} and Enzo Emanuele and Yusuf Yilmaz and Fontana, {Jacopo M.} and Luigi Vignali and Chiara Boiocchi and Ilaria Sbarsi and Mariaclara Cuccia",

year = "2008",

month = apr,

doi = "10.1016/j.arcmed.2007.11.003",

language = "English",

volume = "39",

pages = "320--325",

journal = "Archives of Medical Research",

issn = "0188-4409",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease

AU - Falcone, Colomba

AU - Geroldi, Diego

AU - Buzzi, Maria P.

AU - Emanuele, Enzo

AU - Yilmaz, Yusuf

AU - Fontana, Jacopo M.

AU - Vignali, Luigi

AU - Boiocchi, Chiara

AU - Sbarsi, Ilaria

AU - Cuccia, Mariaclara

PY - 2008/4

Y1 - 2008/4

N2 - Background: The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis. No data are currently available on the potential prognostic role of this polymorphism in patients with angiographically proven coronary artery disease (CAD). Hereto we sought to address this issue in a large consecutive cohort of patients undergoing coronary revascularization. Methods: A total of 643 CAD patients who underwent myocardial revascularization were followed for 4.2 years (interquartile range: 2.2-8.1 years). The rates of major cardiac adverse events (death, nonfatal myocardial infarction, and unstable angina) were compared according to the -374T/A RAGE polymorphism. Results: During a median follow-up period of 4.2 years, the study endpoint was reached by 126/643 patients (19.6%). We observed adverse cardiac events in 13.4% of patients with AA, 17.5% of those with AT, and 24.2% of those with TT genotype (p

AB - Background: The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis. No data are currently available on the potential prognostic role of this polymorphism in patients with angiographically proven coronary artery disease (CAD). Hereto we sought to address this issue in a large consecutive cohort of patients undergoing coronary revascularization. Methods: A total of 643 CAD patients who underwent myocardial revascularization were followed for 4.2 years (interquartile range: 2.2-8.1 years). The rates of major cardiac adverse events (death, nonfatal myocardial infarction, and unstable angina) were compared according to the -374T/A RAGE polymorphism. Results: During a median follow-up period of 4.2 years, the study endpoint was reached by 126/643 patients (19.6%). We observed adverse cardiac events in 13.4% of patients with AA, 17.5% of those with AT, and 24.2% of those with TT genotype (p

KW - Genetics

KW - Polymorphism

KW - Prognosis

KW - Receptor for advanced glycation end products

UR - http://www.scopus.com/inward/record.url?scp=39149109304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149109304&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2007.11.003

DO - 10.1016/j.arcmed.2007.11.003

M3 - Article

C2 - 18279705

AN - SCOPUS:39149109304

VL - 39

SP - 320

EP - 325

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 3

ER -

The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this